Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update

References

• LipGYTseHFLaneDAAtrial fibrillationLancet2012379981664866122166900
   PubMed Web of Science ®Google Scholar
• de DenusSSanoskiCACarlssonJOpolskiGSpinlerSARate vs rhythm control in patients with atrial fibrillation: a meta-analysisArch Intern Med2005165325826215710787
   PubMedGoogle Scholar
• Lafuente-LafuenteCMoulySLongás-TejeroMAMahéIBergmannJFAntiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trialsArch Intern Med2006166771972816606807
   PubMedGoogle Scholar
• FreemantleNLafuente-LafuenteCMitchellSEckertLReynoldsMMixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillationEuropace201113332934521227948
   PubMed Web of Science ®Google Scholar
• CammJAntiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefitsInt J Cardiol2012155336237121708411
   PubMed Web of Science ®Google Scholar
• DobrevDNattelSNew antiarrhythmic drugs for treatment of atrial fibrillationLancet201037597211212122320334907
   PubMed Web of Science ®Google Scholar
• DobrevDHamadBKirkpatrickPVernakalantNat Rev Drug Discov201091291591621119728
   PubMed Web of Science ®Google Scholar
• FedidaDOrthPMChenJYThe mechanism of atrial antiarrhythmic action of RSD1235J Cardiovasc Electrophysiol200516111227123816302909
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA)Assessment Report for BrinavessLondonEMA2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001215/WC500097150.pdfAccessed April 3, 2013
   Google Scholar
• DorianPPinterAMangatIKorleyVCvitkovicSSBeatchGNThe effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humansJ Cardiovasc Pharmacol2007501354017666913
   PubMed Web of Science ®Google Scholar
• RoyDRoweBHStiellIGCRAFT InvestigatorsA randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillationJ Am Coll Cardiol200444122355236115607398
   PubMed Web of Science ®Google Scholar
• RoyDPrattCMTorp-PedersenCAtrial Arrhythmia Conversion Trial InvestigatorVernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trialCirculation2008117121518152518332267
   PubMed Web of Science ®Google Scholar
• KoweyPRDorianPMitchellLBAtrial Arrhythmia Conversion Trial InvestigatorsVernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trialCir Arrhythm Electrophysiol200926652659
   PubMed Web of Science ®Google Scholar
• PrattCMRoyDTorp-PedersenCAtrial Arrhythmia Conversion Trial (ACT-III) InvestigatorsUsefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillationAm J Cardiol201010691277128321029824
   PubMed Web of Science ®Google Scholar
• StiellIGRoosJSKavanaghKMDickinsonGA multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythmAm Heart J201015961095110120569725
   PubMed Web of Science ®Google Scholar
• CammAJCapucciAHohnloserSHA randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillationJ Am Coll Cardiol201157331332121232669
   PubMed Web of Science ®Google Scholar
• Torp-PedersenCRaevDHDickinsonGButterfieldNNMangalBBeatchGNA randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversionCir Arrhythm Electrophysiol201145637643
   PubMed Web of Science ®Google Scholar
• FedidaDVernakalant (RSD1235): a novel, atrial-selective antifibrillatory agentExpert Opin Investig Drugs2007164519532
   PubMed Web of Science ®Google Scholar
• WettwerEChristTEndigSThe new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillationCardiovasc Res201398114515423341576
   PubMed Web of Science ®Google Scholar
• OrthPMHeskethJCMakCKRSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agentsCardiovasc Res200670348649616545351
   PubMed Web of Science ®Google Scholar
• CarmelietEMubagwaKAntiarrhythmic drugs and cardiac ion channels: mechanisms of actionProg Biophys Mol Biol19987011729785957
   PubMed Web of Science ®Google Scholar
• BurashnikovAAntzelevitchCNew developments in atrial antiarrhythmic drug therapyNat Rev Cardiol20107313914820179721
   PubMed Web of Science ®Google Scholar
• ComtoisPSakabeMVigmondEJMechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlatesAm J Physiol Heart Circ Physiol20082954H1489H150418676686
   PubMed Web of Science ®Google Scholar
• AntzelevitchCBurashnikovAAtrial-selective sodium channel block as a novel strategy for the management of atrial fibrillationAnn N Y Acad Sci201011881788620201889
   PubMedGoogle Scholar
• BurashnikovADi DiegoJMZygmuntACBelardinelliLAntzelevitchCAtrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazineCirculation2007116131449145717785620
   PubMed Web of Science ®Google Scholar
• BurashnikovADi DiegoJMSicouriSFerreiroMCarlssonLAntzelevitchCAtrial-selective effects of chronic amiodarone in the management of atrial fibrillationHeart Rhythm20085121735174219084813
   PubMed Web of Science ®Google Scholar
• BurashnikovAPourrierMGibsonJKLynchJJAntzelevitchCRate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalolCir Arrhythm Electrophysiol201252400408
   PubMed Web of Science ®Google Scholar
• SuzukiTMorishimaMKatoSUedaNHonjoHKamiyaKAtrial selectivity in Na+ channel blockade by acute amiodaroneCardiovasc Res201398113614423341577
   PubMed Web of Science ®Google Scholar
• WakiliRVoigtNKaabSDobrevDNattelSRecent advances in the molecular pathophysiology of atrial fibrillationJ Clin Invest201112182955296821804195
   PubMed Web of Science ®Google Scholar
• ChenYJChenSAChenYCEffects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: implication in initiation of atrial fibrillationCirculation2001104232849285411733406
   PubMed Web of Science ®Google Scholar
• PattersonEJackmanWMBeckmanKJSpontaneous pulmonary vein firing in man: relationship to tachycardia-pause early afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitroJ Cardiovasc Electrophysiol200718101067107517655663
   PubMed Web of Science ®Google Scholar
• VoigtNLiNWangQEnhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillationCirculation2012125172059207022456474
   PubMed Web of Science ®Google Scholar
• AroraRVerheuleSScottLArrhythmogenic substrate of the pulmonary veins assessed by high-resolution optical mappingCirculation2003107131816182112665495
   PubMed Web of Science ®Google Scholar
• KumagaiKTojoHNoguchiHEffects of the Na+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillationJ Cardiovasc Electrophysiol200415121396140115610286
   PubMed Web of Science ®Google Scholar
• SicouriSPourrierMGibsonJKLynchJJAntzelevitchCComparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparationsHeart Rhythm20129342242922019863
   PubMed Web of Science ®Google Scholar
• TianDFrishmanWHVernakalant: a new drug to treat patients with acute onset atrial fibrillationCardiol Rev2011191414421135602
   PubMed Web of Science ®Google Scholar
• DugganSTScottLJIntravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillationDrugs201171223725221275448
   PubMed Web of Science ®Google Scholar
• BronisKMetaxaSKoulourisSManolisASVernakalant: review of a novel atrial selective antiarrhythmic agent and its place in current treatment of atrial fibrillationHospital Chronicles201273171181
   Google Scholar
• Blomstrom-LundqvistCBlomstromPSafety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivityExpert Opin Drug Saf201211467167922632377
   PubMed Web of Science ®Google Scholar
• CialdellaPPedicinoDSantangeliPNovel agents for the acute conversion of atrial fibrillation: focus on vernakalantRecent Pat Cardiovasc Drug Discov2011611821235460
   PubMedGoogle Scholar
• VizzardiESalghettiFBonadeiIA new antiarrythmic drug in the treatment of recent onset atrial fibrillation: vernakalantCardiovasc Ther Epub February 8, 2013
   Google Scholar
• Torp-PedersenCCammAJButterfieldNNDickinsonGBeatchGNVernakalant: Conversion of atrial fibrillation in patients with ischemic heart diseaseInt J Cardiol Epub November 21, 2011
   Web of Science ®Google Scholar
• CammAJToftETorp-PedersenCScene 2 InvestigatorsEfficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trialEuropace201214680480922291438
   PubMed Web of Science ®Google Scholar
• de Riva-SilvaMMontero-CabezasJMSalgado-ArandaRLópez-GilMFontenla-CerezuelaAArribas-YnsaurriagaF1:1 atrial flutter after vernakalant administration for atrial fibrillation cardioversionRev Esp Cardiol2012651110621064 English and Spanish22727797
   PubMed Web of Science ®Google Scholar
• European Heart Rhythm Association; European Association for Cardio-Thoracic SurgeryCammAJKirchhofPGuidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Eur Heart J201031192369242920802247
   PubMed Web of Science ®Google Scholar
• Maastricht University Medical CenterVernakalant versus ibutilide in recent-onset atrial fibrillationClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2012 [updated July 18, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646281. NLM identifier: NCT01646281Accessed April 3, 2013
   Google Scholar
• Medical University of ViennaVernakalant versus ibutilide in recent-onset atrial fibrillationClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2011 [updated February 21, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01447862. NLM identifier: NCT01447862Accessed April 3, 2013
   Google Scholar
• BashLDBuonoJLDaviesGMSystematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillationCardiovasc Drugs Ther201226216717922418856
   PubMed Web of Science ®Google Scholar
• FusterVRydénLECannomDSAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm SocietyACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyCirculation20061147e257e35416908781
   PubMed Web of Science ®Google Scholar
• DuytschaeverMBlaauwYAllessieMConsequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugsCardiovasc Res2005671697615949471
   PubMed Web of Science ®Google Scholar
• EijsboutsSAusmaJBlaauwYSchottenUDuytschaeverMAllessieMASerial cardioversion by class IC Drugs during 4 months of persistent atrial fibrillation in the goatJ Cardiovasc Electrophysiol200617664865416836716
   PubMed Web of Science ®Google Scholar
• BuccellettiFIacominiPBottaGEfficacy and safety of vernakalant in recent-onset atrial fibrillation after the European Medicines Agency approval: systematic review and meta-analysisJ Clin Pharmacol201252121872187822167572
   PubMed Web of Science ®Google Scholar
• LynchJJJrReganCPBeatchGNGleimGWMorabitoCJComparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissuesJ Cardiovasc Pharmacol201361322623223188129
   PubMed Web of Science ®Google Scholar
• CondeDCostabelJPAragonMFlecainide or propafenone vs vernakalant for conversion of recent-onset atrial fibrillationCan J Cardiol Epub March 2, 2013
   Web of Science ®Google Scholar
• AndresenDTrappeHJAntiarrhythmic drug therapy in patients with supraventricular or ventricular tachyarrhythmias in emergenciesAppl Cardiopulm Pathophysiol2012162154161
   Google Scholar
• KodamaIKamiyaKToyamaJAmiodarone: ionic and cellular mechanisms of action of the most promising class III agentAm J Cardiol19998492028
   Google Scholar
• GautierPGuillemareEDjandjighianLIn vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effectsJ Cardiovasc Pharmacol200444224425715243307
   PubMed Web of Science ®Google Scholar
• AliotECapucciACrijnsHJGoetteATamargoJTwenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillationEuropace201113216117321138930
   PubMed Web of Science ®Google Scholar
• VoigtNRozmaritsaNTrauschAInhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillationNaunyn Schmiedebergs Arch Pharmacol2010381325125919760273
   PubMed Web of Science ®Google Scholar